 Millennials and Generation Z are the demographic most likely to go into debt for travel and other experiences. The FDA has approved Eli Lilly's Alzheimer drug, Denonimab, expanding the limited treatment options for the mind-wasting disease. This treatment is not a cure, but instead is meant to slow the progress of the disease. The agency has approved the treatment, which will be sold under the brand name Kisunla for adults in early stages of the illness. Nearly 7 million Americans have the condition.